Page last updated: 2024-11-07
bay-s 9435
Description
sulfociprofloxacin: structure given in first source; ciprofloxacin metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
sulfociprofloxacin : An organosulfonic acid that is ciprofloxacin carrying a sulfo group at position 4 of the piperazine ring. It is a metabolite of ciprofloxacin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 128781 |
| CHEBI ID | 192798 |
| SCHEMBL ID | 13576360 |
| MeSH ID | M0166955 |
Synonyms (22)
| Synonym |
|---|
| sulfociprofloxacin |
| FT-0665059 |
| 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-sulfopiperazino)-3-quinolinecarboxylic acid |
| bay s 9435 |
| CHEBI:192798 |
| ciprofloxacin piperazinyl-n(4)-sulfate |
| 1-cyclopropyl-6-fluoro-4-oxo-7-(4-sulfopiperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid |
| bay-s-9435 |
| bay-s 9435 |
| 105093-21-8 |
| 1-cyclopropyl-6-fluoro-4-oxo-7-(4-sulfopiperazin-1-yl)quinoline-3-carboxylic acid |
| 7h561zf07l , |
| 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-sulfo-1-piperazinyl)- |
| unii-7h561zf07l |
| ciprofloxacin piperazinyl-n4-sulfate |
| 4-sulfociprofloxacin |
| SCHEMBL13576360 |
| DTXSID20146939 |
| J-001343 |
| AKOS030255952 |
| Q27268280 |
| ciprofloxacinpiperazinyl-n4-sulfate |
Research Excerpts
Pharmacokinetics
Dosage Studied
Roles (2)
| Role | Description |
|---|
| drug metabolite | null |
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (7)
| Class | Description |
|---|
| N-arylpiperazine | |
| quinolinemonocarboxylic acid | Any aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent. |
| quinolone | |
| organosulfonic acid | An organic derivative of sulfonic acid in which the sulfo group is linked directly to carbon. |
| cyclopropanes | Cyclopropane and its derivatives formed by substitution. |
| fluoroquinolone antibiotic | An organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system. |
| quinolone antibiotic | An organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.27
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.27 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.21 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |